Raymond James Financial’s KalVista Pharmaceuticals KALV Stock Holding History

Raymond James Financial’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-140,651	Closed	-$2.83M	–	5495
2026 Q1	$2.83M	Buy	140,651 +11,134	+9%	+$179K	﹤0.01%	3070
2025 Q4	$2.09M	Sell	129,517 -19,789	-13%	-$262K	﹤0.01%	3240
2025 Q3	$1.82M	Buy	149,306 +48,271	+48%	+$667K	﹤0.01%	3240
2025 Q2	$1.14M	Buy	+101,035	New	+$1.24M	﹤0.01%	3486

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Raymond James Financial's KALV Position: Q2 2026 in Review

Raymond James Financial sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 140,651 shares — an estimated $2.83M sold.

Raymond James Financial first reported a position in KALV in Q2 2025 and held it in 4 quarters. The position peaked at $2.83M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Raymond James Financial reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Raymond James Financial sold 140,651 KalVista Pharmaceuticals shares in Q2 2026, an estimated $2.83M.
Raymond James Financial first reported a position in KalVista Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Raymond James Financial's KalVista Pharmaceuticals position peaked at $2.83M in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.